On August 10, INNOCARE rose 5.17% in regular trading, reaching HKD 15.04 per share, with turnover of approximately HKD 59.41 million. The rally was driven by a cluster of positive clinical readouts across the company's autoimmune pipeline, coupled with a 9.9% cumulative gain in its A-share listing the prior week, prompting catch-up buying in the Hong Kong-listed shares.

On the pipeline front, the company's TYK2 allosteric inhibitor fadeucravacitinib (ICP-488) achieved the primary endpoint in its Phase III registrational trial for moderate-to-severe plaque psoriasis in late July, with plans to advance regulatory filing. Earlier in July, another TYK2 inhibitor soficitinib (ICP-332) met the primary endpoint in its Phase III trial for moderate-to-severe atopic dermatitis as well as in its Phase II study for non-segmental vitiligo, demonstrating statistically significant and clinically meaningful efficacy.

The broader biotech sector also rallied on the same session, with AKESO up 4.4%, REMEGEN up 4.29%, and 3SBIO up 3.39%, reflecting positive industry sentiment that further supported individual stock gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)